What is Insmed's expected EPS for Q2 2026?

Analysts expect Insmed (INSM) to report consensus EPS of approximately $-0.69 for Q2 2026. Estimates range from $-1.09 to $-0.05.

What revenue do analysts expect for Insmed in Q2 2026?

The consensus revenue forecast for Insmed (INSM) in Q2 2026 is approximately $393M. Forecasts range from $374M to $414M.

How many analysts cover Insmed?

12 analysts contribute to the Insmed (INSM) Q2 2026 consensus estimate.

Has Insmed beaten earnings estimates recently?

Insmed beat analyst EPS estimates in 1 of the last 1 quarter. Insmed beat revenue estimates in 1 of 1. In the most recent quarter (Q1 2026), Insmed EPS beat by 21.1% and revenue beat by 1.7%.

When does Insmed report Q2 2026 earnings?

Insmed (INSM) is expected to report Q2 2026 earnings on August 6, 2026 before market open.

INSM Q2 2026 earnings estimate

Consensus EPS · Q2 2026

-$0.69

Consensus revenue · Q2 2026

$393M

Analysts

Expected report

Aug 6, 2026

Before open

Upcoming earnings

Locks in 13 days 11 hours · BMO: Locks 8:00 PM ET previous day

Revenue$393M$373.8M – $414.4M

EPS-$0.69-$1.09 – -$0.05

What to watch

Analyst ratings: Mixed

Make your prediction

Analyst consensus

Based on estimates from 12 analysts.

Metric	Low	Consensus	High
Revenue	$373.8M	$393M	$414.4M
EPS	-$1.09	-$0.69	-$0.05
EBITDA	-$403.4M	-$392.5M	-$380.3M
EBIT	-$403.4M	-$392.5M	-$380.3M
Net income	-$204.1M	-$150.4M	-$96.7M

Revenue$393M
EPS-$0.69
EBITDA-$392.5M
EBIT-$392.5M
Net income-$150.4M

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q1 2026	$306M	$300.8M	+1.7%	-$0.76	-$0.96	+21.1%

Q1 2026+1.7%+21.1%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Collecting data

Revision trends appear once we have collected at least two daily snapshots for this period.

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for Insmed (INSM) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 3 analysts.

Low: $161.00
Consensus: $199.45
Median: $200.00
High: $231.00
Current: $106.64
Upside: +87.0%

Upside calculated vs most recent trading price of $106.64.

Consensus across all covering analysts. See the ranking ›

$199.45+87.03%

Analyst ratings

Consensus: Buy — based on 35 analyst ratings.

Buy 33Hold 1Sell 1

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Jul 15, 2026	Wells Fargo	maintain	Overweight	Overweight
Jul 10, 2026	Guggenheim	maintain	Buy	Buy
Jun 22, 2026	Evercore ISI Group	maintain	Outperform	Outperform
Jun 8, 2026	JP Morgan	maintain	Overweight	Overweight
Jun 5, 2026	RBC Capital	maintain	Outperform	Outperform
May 14, 2026	Truist Securities	maintain	Buy	Buy
May 8, 2026	Wells Fargo	maintain	Overweight	Overweight
May 8, 2026	RBC Capital	maintain	Outperform	Outperform
May 8, 2026	Guggenheim	maintain	Buy	Buy
Apr 17, 2026	Roth Capital	maintain	Buy	Buy

Jul 15, 2026Wells FargoOverweight
Jul 10, 2026GuggenheimBuy
Jun 22, 2026Evercore ISI GroupOutperform
Jun 8, 2026JP MorganOverweight
Jun 5, 2026RBC CapitalOutperform
May 14, 2026Truist SecuritiesBuy
May 8, 2026Wells FargoOverweight
May 8, 2026RBC CapitalOutperform
May 8, 2026GuggenheimBuy
Apr 17, 2026Roth CapitalBuy

Frequently asked questions

Insmed (INSM) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

INSM Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation